Neoimmunetechnitis A Clinical Stage Biopharmaceutical Company Based In Rockvillemarylandfounded In 2014The Company Specializes In T Cell Focused Immunotherapiesdeveloping Innovative Therapeutics Aimed At Treating Oncologic And Infectious Diseasesnit Is Publicly Listed On Kosdaq Under The Ticker 950220 The Company S Lead Productnt I7Is A Long Acting Human Interleukin 7 Therapy Designed To Expand T Cell Populations In Cancer Patients And Address Low Lymphocyte Countsnt I7 Is Currently Undergoing Clinical Trials For Various Indicationsincluding Solid Tumors And As A Vaccine Adjuvantneoimmunetech Focuses On Combination Therapiesintegrating Nt I7 With Existing Treatments To Enhance Patient Outcomeswith A Dedicated Team Of 82 Employeesthe Company Is Committed To Advancing Its Research And Development Efforts In The U Sand Accessing The Asian Market Through Its South Korean Listing
No conferences found for this company.
| Company Name | Neoimmune Tech Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
